Protagonist Therapeutics (MEX:PTGX) Other Operating Expense: MXN0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:PTGX Protagonist Therapeutics Inc MEX:PTGX
47 GF Score
Price MXN1,565.33
GF Value MXN757.20
! 6 Warning Signs
View Full Analysis

What is Protagonist Therapeutics Other Operating Expense?

Protagonist Therapeutics MEX:PTGX 47 Other Operating Expense is MXN0 Mil as of Jun. 2026. GuruFocus rates MEX:PTGX with a GF Score™ of 47/100 and a GF Value™ of MXN757.20. The stock has 6 warning signs investors should review.

Protagonist Therapeutics's Other Operating Expense for the three months ended in Jun. 2026 was MXN0 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was MXN0 Mil.

Protagonist Therapeutics's quarterly Other Operating Expense declined from Dec. 2025 (MXN0 Mil) to Mar. 2026 (MXN-0 Mil) but then increased from Mar. 2026 (MXN-0 Mil) to Jun. 2026 (MXN0 Mil).

Protagonist Therapeutics's annual Other Operating Expense increased from Dec. 2023 (MXN-0 Mil) to Dec. 2024 (MXN0 Mil) but then declined from Dec. 2024 (MXN0 Mil) to Dec. 2025 (MXN-0 Mil).

Protagonist Therapeutics Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Protagonist Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protagonist Therapeutics Other Operating Expense Chart

Protagonist Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 -0.00 -0.00 0.00 -0.00

Protagonist Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.00 0.00
MEX:PTGX
47GF Score
Protagonist Therapeutics Inc MEX:PTGX
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protagonist Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of MXN0 Mil mean?
Protagonist Therapeutics (MEX:PTGX) has a Other Operating Expense of MXN0 Mil as of Jun. 2026. Other operating expenses that a company records on its income statement. View historical data on Protagonist Therapeutics and its competitors.
Is Protagonist Therapeutics' Other Operating Expense too high?
Protagonist Therapeutics' current Other Operating Expense is MXN0 Mil. Overall, Protagonist Therapeutics has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Protagonist Therapeutics' Other Operating Expense compare to CRNX and SYRE?
Protagonist Therapeutics' Other Operating Expense of MXN0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Protagonist Therapeutics and its competitors. Protagonist Therapeutics's current Other Operating Expense is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagonist Therapeutics stock overvalued right now?
Protagonist Therapeutics (MEX:PTGX) has a current Other Operating Expense of MXN0 Mil. The stock's GF Value™ is MXN757.20, compared to a current price of MXN1,565.33 — trading 106.7% above its estimated fair value. The current Other Operating Expense is MXN0 Mil. Protagonist Therapeutics' overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Protagonist Therapeutics (MEX:PTGX), the current Other Operating Expense is MXN0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Protagonist Therapeutics (MEX:PTGX) Overvalued in 2026?

Based on GuruFocus' analysis, Protagonist Therapeutics stock appears to be overvalued. The current stock price of MXN1,565.33 is trading 106.7% above its estimated GF Value™ of MXN757.20.

Key valuation signals for MEX:PTGX:

  • Other Operating Expense: MXN0 Mil
  • GF Value™: MXN757.20 vs. price of MXN1,565.33 (106.7% above fair value)
  • GF Score™: 47/100 with 6 warning signs

No single metric tells the full story. See the MEX:PTGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Protagonist Therapeutics Business Description

Other Exchanges PTGX:USA
Address 7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
47GF Score

Get the complete analysis for MEX:PTGX

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,565.33
Price
MXN757.20
GF Value